Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS
PA Calabresi, NS Fields, HW Maloni, A Hanham… - Neurology, 1998 - AAN Enterprises
PA Calabresi, NS Fields, HW Maloni, A Hanham, J Carlino, J Moore, MC Levin…
Neurology, 1998•AAN EnterprisesTransforming growth factor (TGF)-β2 is a pleiotropic cytokine associated with remissions in
multiple sclerosis (MS) and amelioration of allergic encephalomyelitis. We assessed the
safety of TGF-β2 in an open-label trial of 11 patients with secondary progressive (SP) MS.
Five patients had a reversible decline in the glomerular filtration rate. There was no change
in expanded disability status scale or MRI lesions during treatment. Systemic TGF-β2 may
be associated with reversible nephrotoxicity, and further investigation of its therapeutic …
multiple sclerosis (MS) and amelioration of allergic encephalomyelitis. We assessed the
safety of TGF-β2 in an open-label trial of 11 patients with secondary progressive (SP) MS.
Five patients had a reversible decline in the glomerular filtration rate. There was no change
in expanded disability status scale or MRI lesions during treatment. Systemic TGF-β2 may
be associated with reversible nephrotoxicity, and further investigation of its therapeutic …
Transforming growth factor (TGF)-β2 is a pleiotropic cytokine associated with remissions in multiple sclerosis (MS) and amelioration of allergic encephalomyelitis. We assessed the safety of TGF-β2 in an open-label trial of 11 patients with secondary progressive (SP) MS. Five patients had a reversible decline in the glomerular filtration rate. There was no change in expanded disability status scale or MRI lesions during treatment. Systemic TGF-β2 may be associated with reversible nephrotoxicity, and further investigation of its therapeutic potential in MS should be performed with caution.
American Academy of Neurology